Currently, Doug is CEO of Health2047, an AMA-funded integrated innovation company based in San Francisco that is focused on improving healthcare at a system-level. Additionally, he serves as chairman of the board at both Arrowhead Research (NASDAQ: ARWR) and Vivaldi Biosciences, and is a managing partner at G5 Partners, a Silicon Valley strategic advisory and venture investment firm. Previously, Doug was an investment partner at Bay City Capital, where he was involved in more than 45 investments in life sciences companies. An M.D. who holds a Ph.D in virology, Doug’s areas of expertise span biotechnology, biopharmaceuticals, specialty medical products, and healthcare innovation.